Letko Brosseau & Associates Inc. Has $96.57 Million Position in Pfizer Inc. $PFE

Letko Brosseau & Associates Inc. lowered its position in shares of Pfizer Inc. (NYSE:PFE) by 4.0% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 3,878,438 shares of the biopharmaceutical company’s stock after selling 160,000 shares during the quarter. Pfizer accounts for about 1.6% of Letko Brosseau & Associates Inc.’s investment portfolio, making the stock its 21st biggest holding. Letko Brosseau & Associates Inc.’s holdings in Pfizer were worth $96,573,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Kepler Cheuvreux Suisse SA acquired a new position in shares of Pfizer in the third quarter valued at approximately $16,613,000. Penn Davis Mcfarland Inc. boosted its holdings in shares of Pfizer by 50.9% in the fourth quarter. Penn Davis Mcfarland Inc. now owns 171,332 shares of the biopharmaceutical company’s stock valued at $4,266,000 after buying an additional 57,777 shares during the period. Mackenzie Financial Corp boosted its holdings in shares of Pfizer by 119.6% in the third quarter. Mackenzie Financial Corp now owns 3,106,644 shares of the biopharmaceutical company’s stock valued at $79,157,000 after buying an additional 1,691,773 shares during the period. Pzena Investment Management LLC boosted its holdings in shares of Pfizer by 0.9% in the third quarter. Pzena Investment Management LLC now owns 6,615,598 shares of the biopharmaceutical company’s stock valued at $168,565,000 after buying an additional 56,484 shares during the period. Finally, Ameriprise Financial Inc. boosted its holdings in shares of Pfizer by 48.2% in the third quarter. Ameriprise Financial Inc. now owns 18,373,140 shares of the biopharmaceutical company’s stock valued at $468,174,000 after buying an additional 5,978,927 shares during the period. Institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research reports. Weiss Ratings raised shares of Pfizer from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, May 6th. Daiwa Securities Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a research report on Thursday, February 12th. Wall Street Zen raised shares of Pfizer from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Bank of America cut their price objective on shares of Pfizer from $27.00 to $26.00 and set a “neutral” rating on the stock in a research report on Thursday, April 9th. Finally, Wolfe Research reissued an “underperform” rating and issued a $26.00 price objective on shares of Pfizer in a research report on Thursday, May 14th. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, twelve have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $28.82.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: The FDA approved an expanded indication for HYMPAVZI, broadening use to more hemophilia A/B patients and children, which could increase future sales. Article Title
• Positive Sentiment: Pfizer’s obesity pipeline remains in focus after phase 2b data showed about 16% weight loss, reinforcing optimism that the company may build a meaningful next-generation growth franchise. Article Title
• Neutral Sentiment: BMO Capital kept its Buy rating on Pfizer, adding support for the stock but not changing the core story by itself. Article Title
• Neutral Sentiment: Multiple articles highlighted Pfizer’s obesity strategy and its effort to find new growth after the COVID windfall faded, which is encouraging but still early-stage. Article Title
• Negative Sentiment: Broader commentary on patent cliffs and rising competition in obesity drugs underscores the pressure Pfizer faces to replace lost revenue and prove its pipeline can deliver. Article Title

Pfizer Stock Performance

Shares of PFE stock opened at $25.67 on Wednesday. The company’s fifty day simple moving average is $26.56 and its 200-day simple moving average is $26.31. The company has a quick ratio of 0.94, a current ratio of 1.25 and a debt-to-equity ratio of 0.67. The firm has a market cap of $146.28 billion, a PE ratio of 19.59 and a beta of 0.34. Pfizer Inc. has a 12 month low of $23.11 and a 12 month high of $28.75.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The firm had revenue of $14.45 billion for the quarter, compared to analyst estimates of $13.84 billion. During the same period in the prior year, the firm posted $0.92 earnings per share. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Equities research analysts expect that Pfizer Inc. will post 2.99 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.